The FDA has approved daraxonrasib (Rasonque), a revolutionary drug by Revolution Medicines, which nearly doubled survival rates in pancreatic cancer clinical trials.
Patients who took the daily pill had an average survival time of 13.2 months
Aug 27, 2026
05:29 pm
What's the storyThe US Food and Drug Administration (FDA) has approved a new treatment for pancreatic cancer, a disease known for its high mortality rate.
The drug, daraxonrasib, sold under the brand name Rasonque and produced by Revolution Medicines, was found to nearly double the overall survival time of patients in clinical trials.
FDA approves landmark pancreatic cancer drug
FDA approves ‘game-changing’ pancreatic cancer drug
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
FDA approves new pancreatic cancer drug that could extend patients' lives
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance
FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy
FDA approves breakthrough drug to treat advanced pancreatic cancer
'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival — and is set to $475,000 a year
A clinical trial saw patients on the drug live a median of 13.2 months
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who…
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for…
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on…
The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial
